文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 自然科学 > 生物学 > Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence
侵权投诉

Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence

DNA damage, Mitomycin, cell senescence

Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence

Cell Cycle 11:16, 3132-3140; August 15, 2012; © 2012 Landes Bioscience

Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence

elise McKenna, Frank traganos, Hong Zhao and Zbigniew Darzynkiewicz*

Brander Cancer Research Institute; Department of pathology; New York Medical College; Valhalla, NY USA

Keywords: senescence, metronomic chemotherapy, oncogenes, cell cycle, human non-small cell lung carcinoma, mTOR, γH2AX,

personalized cancer treatment

Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence

Introduction

Cellular senescence, an irreversible cell cycle arrest, was first defined in 1961 when Hayflick and Moorhead observed that normal cells have a finite proliferative capacity. Cells growing in culture were capable of dividing only a certain number of times before entering a state of proliferative arrest.1 The phenomenon has been attributed to the erosion of telomeres every time a cell divides, leading to their dysfunction.2 This type of cell senes-cence, known as intrinsic or replicative senescence, is generally associated with aging.3 More recently a second type, called extrin-sic, premature or stress-induced senescence, has been defined. It can be triggered by oncogene activation, inactivation of tumor suppressor genes, persistent replication stress, oxidative stress or treatment of cells with DNA damaging drugs or radiation.4

Cell senescence plays a number of different roles, some of which specifically relate to cancer. In some instances senescence acts as a barrier to cancer by preventing normal cells from under-going tumorigenesis.5,6 Another role is in response to cancer treat-ment. Traditional cytotoxic chemotherapy regimens are designed to kill tumor cells through the process of apoptosis.7 While induction of apoptosis is predominant, the induction of senes-cence has also been seen in some types of solid tumors during chemotherapy.8 It is difficult to assess, however, what role, if any, induction of senescence in tumor cells plays in instances where chemotherapy proves effective.

*Correspondence to: Zbigniew Darzynkiewicz; Email: darzynk@nymc.eduSubmitted: 06/18/12; Revised: 07/16/12; Accepted: 07/16/12doc.guandang.net

The activation of oncogenes and/or inhibition of tumor sup-pressor genes are a hallmark of most cancers.9 These events pre-dispose or cause cells to undergo senescence.10-13 It is reasonable to expect, therefore, that under similar stress conditions, cancer cells that have constitutively activated oncogenes or dysfunctional tumor suppressors may be more prone to undergo senescence than normal cells. Given the fact that cytotoxic chemotherapy provided at the maximum tolerated dose (MTD) is generally highly toxic, strategies may be designed to use chemotherapy at much lower concentrations to render tumor cells senescent, thereby minimizing some of the drug-induced toxicity.

For years, the acceptance of antitumor drugs by the FDA was based on response criteria assessed by tumor shrinkage visualized by CT, MRI or traditional X-ray examination. Tumor shrinkage observed this way most likely occurs as a result of cell death by apoptosis. Assessment of the tumor response by its size reduction criteria precluded the detection of potential treatment benefits that could be mediated by induction of senescence of tumor cells.Interestingly, it has recently been shown that some patients benefit from a non-traditional regimen known as metronomic chemotherapy, defined as continuous or frequent treatment with low doses of anticancer drugs.14 While it has generally been assumed that such treatment inhibits tumor angiogenesis,15 no evidence exists as to whether, and to what extent, the induction of cell senescence of the tumor cells contributes to beneficial effects of metronomic therapy.

Cell Cycle Volume 11 Issue 16

第1页

TOP相关主题

你可能喜欢

热门文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email